Vaccines
Sinovac Commences Phase II Clinical Trial for EV71 Vaccine
Published in Vaccine Weekly, July 13th, 2011
2011 JUL 13 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced the commencement of the Phase II clinical trial for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD). The safety observation results from the EV71 vaccine Phase I trial completed in May 2011 showing good safety and tolerance profiles for all three age groups (adult, children and infant groups) and the preliminary immunogenicity study results showed the vaccine can induce good immune responses.
The purpose of the Phase II clinical trial is to determine the dosage level through evaluating the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2011-07-13)
More Articles from Vaccine Weekly
- Heart Attack
New Findings in Heart Attack Described by T.J. Marrie and Co-Researchers - Vaccines
New Vaccines Study Results Reported from I.A. Menegolla et al - Vaccines
Beyond Darwin: Evolving new functions - Infectious Diseases
Data on Infectious Diseases Reported by Researchers at Institute for Systems Biology - Vaccines
Data on Vaccines Discussed by Researchers at University of Guelph - Vaccines
Data on Vaccines Reported by Researchers at Beth Israel Deaconess Medical Center - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
